Molecularly targeted therapies for advanced prostate cancer include castration modalities
that suppress ligand-dependent transcriptional activity of the androgen receptor (AR) …

PURPOSE: Androgen receptor (AR) is expressed in the majority of human prostate cancers.
For a better understanding of prostate carcinoma events it is necessary to present findings …

“You can observe a lot just by watching.”—Yogi Berra The androgen receptor (AR) is a
resilient foe. Since the landmark studies of Huggins et al1 demonstrated the sensitivity of …

Background Genomic alterations to the androgen receptor (AR) are common in metastatic
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …

Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been
treated by hormonal therapy. Almost all prostate cancer patients initially respond to …

Highlights•Androgen receptor (AR) signaling is a critical driver of prostate cancer cell
proliferation and survival.•Alterations in AR and peripheral production of androgens promote …

The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. It
consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (HR) …

Androgen receptor (AR)-mediated signaling is critical to the growth and survival of prostate
cancer. Although medical castration and antiandrogen therapy can decrease AR activity and …

Background A significant subset of prostate cancer (PC) patients with a castration-resistant
form of the disease (CRPC) show primary resistance to androgen receptor (AR)-targeting …

The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant
prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity …